BSECompany Update4d ago · 14 Nov 2026, 04:33 pm
Statement of deviation or variation for the quarter ended on September 30, 2026 on the use of proceeds of funds raised through Qualified institutional placement (QIP)
Orchid Pharma Ltd · 524372
✦ AI SummaryResults
Orchid Pharma Ltd has filed a statement of deviation or variation for the quarter ended September 30, 2026, on the use of proceeds of funds raised through Qualified Institutional Placement (QIP). The company has reallocated the QIP proceeds from the API Facility in Alathur to other projects, citing changes in the business environment and strategic requirements.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk6/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Orchid Pharma Ltd - 524372 - Statement Of Deviation Or Variation For The Quarter Ended September 30, 2026 On The Use Of Proceeds Of Funds Raised Through Qualified Institutional Placement (QIP)
Attachments (1)
📄pdf
Download →
10cc6f1d-d25f-4a1a-b8ac-f6a65d050598.pdf
View document text
OrchidPharm~~
-- A DhanukaGroup Company -----------------------------------
November 14, 2026
National Stock Exchange of India Limited, SSE Limited
Exchange Plaza, Sandra Kurla Complex, Phiroc Jeejeebhoyi owers,
Sandra (E), Mumbai-400051 Dalal Street, Fort, Mumbai-400001
Symbol: ORCHPHARMA Scrip Code: 524372
Subject: Statement of deviation or variation for the quarter ended September 30,
2026 on the use of proceeds of Funds raised through Qualified Institutional
Placement (QiP)
Dear Sir/Madam,
With reference to aforesaid subject and pursuant to Regulation 32 of the SESI (Listing
Obligations and Disclosure Requirements) Regulations, 2015 read with SESI Master Circular
SESI/ HO/49j14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, Statement of
Deviation for the quarter ended September 30, 2026, duly reviewed by the Audit Committee
of the Company is attached herewith.
You are requested to kindly take the same on record
For Orchid Pharma Limite~
p ya
Co pany Secretary & Compliance Officer
embership No.: F10698
+91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994
Registered Office: Corporate Office:
Orchid Pharma Limited 15th Floor, Tower 1. DLF Corporate Greens, Sector 74A,
Plot Nos. 121-128, 128A-133, 138-151. 159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India
Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India.
OrchidPharm~~
-- A DhanukaGroup Company ---,.....---------------------------------
STATEMENT OF DEVIATION OR VARIATION UNDER REGULATION 32 OF SEBI
(LISTING OBLIGATIONS AND DISCLOSURE REOUIREMENTS1REGULATIONS, 2015
FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE,
QUALIfIED INSTITUTIONS PLACEMENT ETC .
Name of listed entity Orchid Pharma Limited
Mode of Fund Raising Qualified Institutions Placement
Date of Raising Funds June 27, 2023
Amount Raised RsAOO Crores
Report fiied for Quarter ended September 30, 2026
Monitoring Agency Applicable
Monitoring Agency Name, if applicable Care Ratings Limited
Is there a Deviation / Variation in use Yes
of funds raised
If yes, whether the same is pursuant to Yes
change in terms of a contract or objects,
which was approved by the
shareholders
If Yes, Date of shareholder Approval September 20, 2025
Explanation for the Deviation I In view of changes in the business environment
Variation and to meet current strategic requirements, the
Company has modified the allocation of the QIP
Proceeds. The commencement of "new block at
API Facility of the Company in Alathur" project has
been postponed to a later stage. Therefore, QIP
Proceeds allotted to API Facility in Alathur has
been reallocated with the approval of shareholders
at the AGM held on September 30, 2025, to
mitigate such additional financial burden, improve
profit and ensure the best possible utilization of
the QIP proceeds in the overall interest of the
Company and its shareholders.
Comments of the Audit Committee after As per attached Annexure
review
Comments of the auditors, if any NA
Objects for which funds have been l. Investment in our wholly owned Subsidiary,
raised and where there has been a Orchid Bio-Pharma Limited, ("OBPL")
deviation, in the following table for setting up a new manufacturing facility in
Jammu ("Jammu Manufacturing Facility");
2. Repayment/prepayment, in full or in part, of
certain outstanding borrowings availed by our
Company;
3. Funding capital expenditure requirements for
setting up a new block at API Facility of the
Company in Alathur, Tamil Nadu; and
4. General corporate purposes.
---------'!ik-- -
+91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994
Registered Office: Corporate Office:
Orchid Pharma Limited 15th Floor, Tower 1, DLF Corporate Greens, Sector 74A,
Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India
Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India.
OrchidPharm~W
-- A DhanukaGroup Company -------------------------------------
I Sr. I Original Object I Modified Original Modified I Funds Amount of I Rema
No , Object, Allocatio allocatio I Utilised Deviation/ rks ii
if any n (Rs. in n, , (Rs. in Variation any
(Rs. in Lakhs) if any Lakhs) for the
Lakhs) (Rs. in quarter
lakhs) according
applicable
object (Rs.
in Lakhs)
1 Investment in OBPL for No 9000 13500 13500
setting up Jammu
Manufacturing Facility
2 Repayment/prepayme No 14100 19546 19546 o
nt, in full or in part, of
certain outstanding
borrowings availed by
our Company
3 Funding capital No 9982 36 36
expenditure
requirements for
setting up a new block
at the API Facility of
the Company in
Alathur, Tamil Nadu
4 General corporate No 6098* 6372 6372 0
purposes ("GCP")
As per the QIP offer document the amount allocated for GCP was Rs.6098 Lakhs which was
on the basis of proposed net proceeds after issue expenses, being Rs.39180 Lakhs. However,
net Proceeds transf~E.r..ed to Monitoring Account was Rs.39454 Lakhs as against the proposed
Net Proceeds of Rs.39;1'80 Lakhs, therefore the GCP was revised to Rs.274 lakhs has been
included in the GCP and th'erefore the GCP balance was revised to Rs.6372 Lakhs.
&. Compliance Officer
+91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994
Registered Office: Corporate Office:
Orchid Pharma Limited 15th Floor, Tower 1, DLF Corporate Greens, Sector 74A,
Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India
Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India.
OrchidPharm~W
-- A Dhanuka Group Company ---------------------------------------
Annexure
So· i Para I Particulars/ Item Head Comments of Monitoring Comments of Audit I
No No. of Agency Committee
Report
1 3 Whether all utilization is as The company revised the · The comments of f'.1onitoring
per the disclosure in the allocation of QIP proceeds Agency are self-explanatory
Offer Document? among the objects specified
in the offer document,
pursuant to shareholders'
approval obtained through
the AGM resolution dated
September 20, 2025.
Accordingly, the utilisation of
funds is now being
undertaken in line with the
revised allocation schedule.
2 3 Whether shareholder Change in allocation of funds The comments of Monitoring
approval has been obtained towards the objects of the Agency are self-explanatory
in case of material deviations issue was approved by
from expenditures disclosed shareholders vide AGM
in the Offer Document? resolution dated September
20, 2025.
3 3 Whether the means of The company revised the The comments of Monitoring
finance for the disclosed allocation of QIP proceeds Agency are self-explanatory
objects of the issue have among the objects specified
changed? in the offer document,
pursuant to shareholders'
approval obtained through
the AGM resolution dated
September 20, 2025.
Accordingly, the utilisation of
funds is now being
undertaken in line with the
revised allocation schedule
4 3 Whether all No specific list of statutory/ The comments of Monitoring
Government/statutory Govt Approvals was Agency are self-explanatory
approvals related to the mentioned in the offer
object(s) have been document for the purpose of
obtained? monitoring. As per the AGM
dated Sep 20, 2025, no
further investment is
expected towards Alathur
proiect from QIP proceeds.
5 3 Whether all arrangements The company has spent Rs. The comments of Monitoring
pertaining to technical 3.77 crores towards Agency are self-explanatory
aSSistance/collaboration are technical know-how.
in operation?
6 3 Are there any There is significant delay in The Land acquisition task has
favorable/unfavorable the implementation of the been given to Land
events affecting the viability manufacturing facility under aggregator who is getting the
of these object(s)? Orchid Bio Pharma Limited in land from various farmers.
Jammu, Commercial Getting the agreement
ci~erations are now expected signed from various farmers
to commence by February has taken
[Showing first 8,000 characters — download PDF for full document]